Gregory M. Shutske - Pittstown NJ, US James A. Hendrix - Hillsborough NJ, US John G. Jurcak - Bethlehem PA, US Brian S. Freed - Phillipsburg NJ, US Nicholas J. Hrib - Hillsborough NJ, US Reda G. Hanna - Allentown PA, US
The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as Dantagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of Dreceptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
David Roger Borcherding - Bangor PA, US Alexandre Gross - Jersey City NJ, US Patrick W. Shum - Flemington NJ, US Nicole Willard - Doylestown PA, US Brian S. Freed - Phillipsburg NJ, US
Richard C. Allen - Flemington NJ Grover C. Helsley - Stockton NJ R. Richard L. Hamer - Lebanon NJ Brian S. Freed - Somerset NJ John I. White - Chapel Hill NC Lawrence L. Martin - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Bridgewater NJ
International Classification:
C07D33374 C07D31300 A61K 3138 A61K 31335
US Classification:
549 48
Abstract:
This invention relates to N-hydroxy-dibenz�b,e!oxepinalkylamines, N-hydroxy-dibenz�b,e!oxepinalkanoic acid amides and related heterocyclic analogues of the formula ##STR1## where X together with the carbon atoms to which it is attached forms a benzene or thiophene ring; W and Z are independently hydrogen, halogen, loweralkyl, or trifluoromethyl; R. sup. 1 is hydrogen, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; R. sup. 2 is loweralkyl, cycloalkyl, arylloweralkyl, loweralkoxycarbonyl, loweralkylcarbonyl, arylcarbonyl or arylloweralkylcarbonyl; m is 0 or 1 and n is an integer of 0 to 4 or the pharmaceutically acceptable salts thereof. The compounds of this invention are useful as analgesics and topical antiinflammatory agents for the treatment of various dermatoses and agents for the treatment of conditions where accumulation of cyclooxygenase and/or lipoxygenase metabolites is a causative factor.
Aminoalkyloximes For Treating Depression And Affective Disorders
Gregory M. Shutske - Pittstown NJ Brian S. Freed - Phillipsburg NJ John D. Tomer - Perkasie PA R. Richard L. Hamer - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Cincinnati OH
International Classification:
C07D29513 A61K 31445 A61K 31535 A61K 3154
US Classification:
514331
Abstract:
Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Gregory M. Shutske - Pittstown NJ Brian S. Freed - Phillipsburg NJ John D. Tomer - Perkasie PA R. Richard L. Hamer - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Cincinnati OH
International Classification:
C07D23364 C07D23361 A61K 31415
US Classification:
514399
Abstract:
Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Gregory M. Shutske - Pittstown NJ Brian S. Freed - Phillipsburg NJ John D. Tomer - Perkasie PA R. Richard L. Hamer - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Cincinnati OH
International Classification:
C07D29513 C07D20708 C07D40304 C07D40312
US Classification:
514428
Abstract:
Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Gregory M. Shutske - Pittstown NJ Brian S. Freed - Phillipsburg NJ John D. Tomer - Perkasie PA R. Richard L. Hamer - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Cincinnati OH
International Classification:
C07D21132 C07D 4010 C07D40106 A61K 31445
US Classification:
514330
Abstract:
Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
Gregory M. Shutske - Pittstown NJ Brian S. Freed - Phillipsburg NJ John D. Tomer - Perkasie PA R. Richard L. Hamer - Lebanon NJ
Assignee:
Hoechst Marion Roussel, Inc. - Cincinnati OH
International Classification:
C07D40312 C07D40304 C07D29513 C07D20708
US Classification:
514212
Abstract:
Novel aminoalkyloximes, precursors and processes for the preparation thereof, and methods of treating depression and obsessive compulsive disorders are described.
"The takeaway capacity we have secured will allow greater flexibility and market optionality for our Permian production, including increasing volumes from our recent discovery at Alpine High," Brian Freed, senior vice president with Apache's Midstream and Marketing unit, said in a separate statement
Date: Dec 21, 2017
Category: Business
Source: Google
Symantec Ousts CEO Enrique Salem in Favor of Chairman
Bennett is known for driving operational progress andfocused product delivery, said Brian Freed, an analyst atWunderlich Securities Inc. in Memphis, Tennessee, who has a buyrecommendation on the stock. The combination of consistentexecution and operational discipline is exactly the orderSyma
Date: Jul 25, 2012
Category: Business
Source: Google
VMware Buys Nicira for $1.26 Billion Adding Network Software
If they dont raise guidance as a result of thisacquisition people will think they bought their way to theearnings forecast for the year, said Brian Freed, an analystat Wunderlich Securities Inc. in Denver. Still, its a goodstrategic fit. Network virtualization is a logical place forVMware
Date: Jul 23, 2012
Category: Sci/Tech
Source: Google
Quest Gets Superior Bid to Insight Venture's Offer
Wunderlich Securities analyst Brian Freed said Dell has seemed to be "the lead contender" in the race to buy thecompany because Quest would expand the computer and hardware maker's software offerings without the overlap that otherpotential suitors would face.
Date: Jun 14, 2012
Category: Business
Source: Google
Quest Surges on $25.50-a-Share Buyout Offer Topping Insight
"The likely outcome here is Quest gets sold at $25.50," said Brian Freed, an analyst at Wunderlich Securities in Denver, in an interview today. "You might see Insight raise its bid to match, but I really don't see a bidding war here."
Date: Jun 14, 2012
Category: Business
Source: Google
New suitor makes higher, $2.17-billion bid for Quest Software
"If you asked me to bet on it, I'd say it's 50-50 odds that Dell is the strategic bidder," said Brian Freed, and analyst for Wunderlich Securities. "Dell is the most logical fit because they can leverage every element of Quest's portfolio."
Date: Jun 14, 2012
Category: Business
Source: Google
Quest Received Multiple Buyout Proposals During Shop Period
They now appear very likely to take a superior offer,said Brian Freed, an analyst at Wunderlich Securities in Denver,who has a hold rating on the shares. It either means someoneelse makes a bid superior to Insight, or Insight moves up itsbid.
The move to go private is, while unusual, not unprecedented, and could provide an operational advantage to the company, said Brian Freed, a financial analyst for Wunderlich Securities who covers the company. Quest and Insight, which has worked with the company for several years, might feel that Ques